Australia's medical cannabis prescriptions jumped from 231 in 2017 to over one million by 2024, but regulatory complexity, cost barriers, and provider knowledge gaps persist.
Health policy makers, medical cannabis regulators, international cannabis program designers
What the researchers found
Prescriptions grew from 231 (2017) to over 1 million (early 2024) generating AUD $445.6M market value. Key barriers: monthly costs of $200-600, uneven rural access, variable provider knowledge, tangled federal-state regulations, and heavy import dependence. Compared to Canada, Germany, and the Netherlands, Australia's approach is relatively restrictive on reimbursement and training.
Why it matters
Australia is one of the world's largest medical cannabis markets, and the lessons from its regulatory growing pains can help other countries avoid similar pitfalls as they develop their own programs.
The numbers in context
Prescriptions: 231 (2017) to 1M+ (early 2024). Market value: AUD $445.6M. Monthly patient costs: $200-600. Comparative analysis across 4 countries (Australia, Canada, Germany, Netherlands).
How the study worked
Narrative review examining Australian medical cannabis policy evolution from 2016 to 2024, with comparative analysis of Canadian opt-out insurance, German pharmacist-led dispensing, and Dutch community-growth models.
What this study cannot tell us
Narrative review without systematic methodology. Policy analysis based on available public data which may be incomplete. International comparisons complicated by different healthcare systems and cultural contexts.
How to read the evidence
Policy review synthesizing regulatory data and international comparisons without systematic evidence assessment.
When this study was published
Published 2026, covering Australian policy from 2016 to 2024.
The bigger picture
Australia's experience shows that legalizing medical cannabis is just the first step — building an accessible, affordable, and well-informed system requires sustained policy attention to equity, education, and supply chain development.
Questions still open
- Should Australia extend PBS subsidies to medical cannabis? Could domestic cultivation reduce costs and import dependence? What educational standards should be mandated for prescribers?
Common questions
How big is Australia's medical cannabis market?
What are the barriers to medical cannabis access in Australia?
Read the original research
Evolving health policy and regulatory oversight of medicinal cannabis in Australia: lessons for sustainable integration.
Journal of cannabis research, 8(1), 31
Citation
Lim, Enoch Chi Ngai; Lim, Chi Eung Danforn. (2026). Evolving health policy and regulatory oversight of medicinal cannabis in Australia: lessons for sustainable integration.. Journal of cannabis research, 8(1), 31. https://doi.org/10.1186/s42238-026-00394-z